Cited by 180SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesPoxvirus research and outbreaks

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets

Open access

CZUB, M, WEINGARTL, H, CZUB, S, HE, R, CAO, J·2005·Vaccine

DOI 10.1016/j.vaccine.2005.01.033PMC PMC7115540

Open this paper in CoChat — free account

Abstract

Severe acute respiratory syndrome (SARS) caused by a newly identified coronavirus (SARS-CoV) remains a threat to cause epidemics as evidenced by recent sporadic cases in China. In this communication, we evaluated the efficacy and safety of two SARS vaccine candidates based on the recombinant modified vaccinia Ankara (MVA) expressing SARS-CoV spike or nucleocapsid proteins in ferrets. No clinical signs were observed in all the ferrets challenged with SARS-CoV. On the other hand, vaccination did not prevent SARS-CoV infection in ferrets. In contrast, immunized ferrets (particularly those immunized with rMVA-spike) exhibited significantly stronger inflammatory responses and focal necrosis in liver tissue after SARS-CoV challenge than control animals. Thus, our data suggest that enhanced hepatitis is linked to vaccination with rMVA expressing SARS-CoV antigens.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2005.01.033

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R. P., Icenogle, J. P., Peñaranda, S., Bankamp, B., Maher, K., Chen, M., et al. (2003) · Science · doi:10.1126/science.1085952 · Cited by 2,477
The Genome Sequence of the SARS-Associated Coronavirus
Marra, M. A., Jones, S. J. M., Astell, C. R., Holt, R. A., Brooks-Wilson, A. R., Butterfield, Y. S. N., Khattra, J. S., Asano, J. K., Barber, S., Chan, S. Y., et al. (2003) · Science · doi:10.1126/science.1085953 · Cited by 2,027
Self-citation
SARS virus infection of cats and ferrets
Martina, B. E. E., Haagmans, B. L., Kuiken, T., Fouchier, R. A. M., Rimmelzwaan, G. F., van Amerongen, G., Peiris, M. J. S., Lim, W. W. L., & Osterhaus, A. D. M. E. (2003) · Nature · doi:10.1038/425915a · Cited by 571
SARS-associated viral hepatitis caused by a novel coronavirus: Report of three cases
Chau, T., Lee, K.-C., Yao, H., Tsang, T. Y. O., Chow, T., Yeung, Y.-C., Choi, K., Tso, Y.-K., Lau, T., Lai, S.-T., et al. (2004) · Hepatology · doi:10.1002/hep.20111 · Cited by 422
Compact, Synthetic, Vaccinia Virus Early/Late Promoter for Protein Expression
Chakrabarti, S., Sisler, J. R., & Moss, B. A. (1997) · BioTechniques · doi:10.2144/97236st07 · Cited by 391
Antibody‐dependent enhancement of viral infection: molecular mechanisms and in vivo implications
Takada, A., & Kawaoka, Y. (2003) · Reviews in Medical Virology · doi:10.1002/rmv.405 · Cited by 332
Monoclonal antibodies to murine hepatitis virus-4 (strain JHM) define the viral glycoprotein responsible for attachment and cell-cell fusion
Collins, A. R., Knobler, R. L., Powell, H., & Buchmeier, M. J. (1982) · Virology · doi:10.1016/0042-6822(82)90095-2 · Cited by 317
Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors
Falkner, F. G., & Moss, B. A. (1988) · Journal of Virology · doi:10.1128/jvi.62.6.1849-1854.1988 · Cited by 317
Antibody-Dependent Enhancement of Virus Infection and Disease
Cancel-Tirado, S. M., & Yoon, K. J. (2003) · Viral Immunology · doi:10.1089/088282403763635465 · Cited by 316
Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization
Vennema, H., de Groot, R. J., Harbour, D. A., Dalderup, M. J. M., Gruffydd-Jones, T., Horzinek, M. C., & Spaan, W. J. M. (1990) · Journal of Virology · doi:10.1128/jvi.64.3.1407-1409.1990 · Cited by 276

Show all 17 references

Sorted by citations

SARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098
Coronaviruses — drug discovery and therapeutic options
Zumla, A. I., Chan, J. F., Azhar, E. I., Hui, D. S. C., & Yuen, K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,711
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,678
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
From SARS to MERS, Thrusting Coronaviruses into the Spotlight
Song, Z., Xu, Y., Bao, L., Zhang, L., Yü, P., Qu, Y., Zhu, H., Zhao, W., Han, Y., & Qin, C. (2019) · Viruses · doi:10.3390/v11010059 · Cited by 1,292
Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus
Weiss, S. R., & Navas-Martin, S. (2005) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.69.4.635-664.2005 · Cited by 1,256
Distinct conformational states of SARS-CoV-2 spike protein
Cai, Y., Zhang, J., Xiao, T., Peng, H., Sterling, S. M., Walsh, R. M., Rawson, S., Rits-Volloch, S., & Chen, B. (2020) · Science · doi:10.1126/science.abd4251 · Cited by 1,221
Coronavirus Infections in Children Including COVID-19
Zimmermann, P., & Curtis, N. C. (2020) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002660 · Cited by 1,134
Immunological considerations for COVID-19 vaccine strategies
Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00434-6 · Cited by 1,015
Genotype and phenotype of COVID-19: Their roles in pathogenesis
Mousavizadeh, L., & Ghasemi, S. (2020) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2020.03.022 · Cited by 961
Coronavirus Pathogenesis
Weiss, S. R., & Leibowitz, J. L. (2011) · Advances in virus research · doi:10.1016/b978-0-12-385885-6.00009-2 · Cited by 926
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Lee, W. S., Wheatley, A. K., Kent, S. J., & DeKosky, B. J. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00789-5 · Cited by 676
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560
Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections
Zimmermann, P., & Curtis, N. C. (2020) · Archives of Disease in Childhood · doi:10.1136/archdischild-2020-320338 · Cited by 513
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
Arvin, A. M., Fink, K., Schmid, M. A., Cathcart, A., Spreafico, R., Havenar-Daughton, C., Lanzavecchia, A., Corti, D., & Virgin, H. W. (2020) · Nature · doi:10.1038/s41586-020-2538-8 · Cited by 485
Coronavirus vaccine development: from SARS and MERS to COVID-19
Li, Y.-D., Chi, W.-Y., Su, J.-H., Ferrall, L., Hung, C., & Wu, T. ‐. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00695-2 · Cited by 486
Human Coronaviruses: Insights into Environmental Resistance and Its Influence on the Development of New Antiseptic Strategies
Geller, C., Varbanov, M., & Duval, R. E. (2012) · Viruses · doi:10.3390/v4113044 · Cited by 444
COVID-19 vaccines: The status and perspectives in delivery points of view
Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375
The COVID-19 pandemic face mask waste: A blooming threat to the marine environment
Dharmaraj, S., Ashokkumar, V., Hariharan, S., Manibharathi, A., Show, P. L., Chong, C. T., & Ngamcharussrivichai, C. (2021) · Chemosphere · doi:10.1016/j.chemosphere.2021.129601 · Cited by 316
Prospects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Prior Immunization with Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus (SARS-CoV) Nucleocapsid Protein Causes Severe Pneumonia in Mice Infected with SARS-CoV
Yasui, F., Kai, C., Kitabatake, M., Inoue, S., Yoneda, M., Yokochi, S., Kase, R., Sekiguchi, S., Morita, K., Hishima, T., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6337 · Cited by 248
Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus
Yong, C. Y., Ong, H. K., Yeap, S. K., Ho, K. L., & Tan, W. S. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01781 · Cited by 224
Contriving Multi-Epitope Subunit of Vaccine for COVID-19: Immunoinformatics Approaches
Dong, R., Chu, Z., Yu, F., & Zha, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01784 · Cited by 224
The Evolution of Poxvirus Vaccines
Sánchez-Sampedro, L., Perdiguero, B., Mejías‐Pérez, E., García‐Arriaza, J., Pilato, M. D., & Estéban, M. (2015) · Viruses · doi:10.3390/v7041726 · Cited by 217
Accelerating antiviral drug discovery: lessons from COVID-19
von Delft, A., Hall, M. D., Kwong, A. D., Purcell, L. A., Saikatendu, K. S., Schmitz, U., Tallarico, J. A., & Lee, A. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00692-8 · Cited by 230
Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity
Ryan, K. A., Bewley, K. R., Fotheringham, S. A., Slack, G. S., Brown, P. J., Hall, Y., Wand, N. I. V., Marriott, A. C., Cavell, B. E., Tree, J. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20439-y · Cited by 191
Peptide Nanoparticles as Novel Immunogens: Design and Analysis of a Prototypic Severe Acute Respiratory Syndrome Vaccine
Pimentel, T. A. P. F., Yan, Z., Jeffers, S. A., Holmes, K. V., Hodges, R. S., & Burkhard, P. (2008) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2008.00746.x · Cited by 182
Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model
Du, L., Zhao, G., He, Y., Guo, Y., Zheng, B., Jiang, S., & Zhou, Y. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.10.031 · Cited by 180
SARS vaccines: where are we?
Roper, R. L., & Rehm, K. E. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.43 · Cited by 183
Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains
Padron-Regalado, E. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00300-x · Cited by 180
Learning from the past: development of safe and effective COVID-19 vaccines
Su, S., Du, L., & Jiang, S. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00462-y · Cited by 169
A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction
Ejemel, M., Li, Q., Hou, S., Schiller, Z. A., Tree, J. A., Wallace, A., Amcheslavsky, A., Yılmaz, N. K., Buttigieg, K. R., Elmore, M. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18058-8 · Cited by 185
Current advances in the development of SARS-CoV-2 vaccines
Awadasseid, A., Wu, Y., Tanaka, Y., & Zhang, W. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.52569 · Cited by 164
Current advancements and potential strategies in the development of MERS-CoV vaccines
Zhang, N., Jiang, S., & Du, L. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.912134 · Cited by 160
Emerging Respiratory Viruses: Challenges and Vaccine Strategies
Gillim-Ross, L., & Subbarao, K. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.00005-06 · Cited by 157
Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine
Kapadia, S. U., Rose, J. K., Lamirande, E. W., Vogel, L., Subbarao, K., & Roberts, A. (2005) · Virology · doi:10.1016/j.virol.2005.06.016 · Cited by 155
A comparative overview of COVID-19, MERS and SARS: Review article
Liu, J., Xie, W., Wang, Y., Xiong, Y., Chen, S., Han, J., & Wu, Q. (2020) · International Journal of Surgery · doi:10.1016/j.ijsu.2020.07.032 · Cited by 146
Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection
Du, L., Zhao, G., Lin, Y., Sui, H., Chan, C. C. S., Ma, S., He, Y., Jiang, S., Wu, C. Y., Yuen, K., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.2.948 · Cited by 137
The Poxvirus Vectors MVA and NYVAC as Gene Delivery Systems for Vaccination Against Infectious Diseases and Cancer
Gómez, C. E., Nájera, J. L., Krupa, M., & Estéban, M. (2008) · Current Gene Therapy · doi:10.2174/156652308784049363 · Cited by 139
Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens
DiNapoli, J. M., Kotelkin, A., Yang, L., Elankumaran, S., Murphy, B. R., Samal, S. K., Collins, P. L., & Bukreyev, A. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703584104 · Cited by 136
Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design
He, Y., Li, J., Heck, S., Lustigman, S., & Jiang, S. (2006) · Journal of Virology · doi:10.1128/jvi.00083-06 · Cited by 135
Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice
Kim, E., Okada, K., Kenniston, T., Raj, V. S., AlHajri, M. M., Farag, E., Alhajri, F. H., Osterhaus, A. D. M. E., Haagmans, B. L., & Gambotto, A. A. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.08.058 · Cited by 135
Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design
Ma, C., Wang, L., Tao, X., Zhang, N., Yang, Y., Tseng, C.-T. K., Li, F., Zhou, Y., Jiang, S., & Du, L. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.08.086 · Cited by 131
Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity
Du, L., Zhao, G., Chan, C. C. S., Sun, S., Chen, M., Liu, Z., Guo, H., He, Y., Zhou, Y., Zheng, B., et al. (2009) · Virology · doi:10.1016/j.virol.2009.07.018 · Cited by 127
Prospects for a MERS-CoV spike vaccine
Zhou, Y., Jiang, S., & Du, L. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1506702 · Cited by 126
COVID-19: Mechanisms of Vaccination and Immunity
Speiser, D. E., & Bachmann, M. F. (2020) · Vaccines · doi:10.3390/vaccines8030404 · Cited by 130
SARS-CoV-2 vaccines: Lights and shadows
Angeli, F., Spanevello, A., Reboldi, G., Visca, D., & Verdecchia, P. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.04.019 · Cited by 125
Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease
Enjuanes, L., DeDiego, M. L., Álvarez, E. A., Deming, D., Sheahan, T., & Baric, R. S. (2007) · Virus Research · doi:10.1016/j.virusres.2007.01.021 · Cited by 119
A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses
Spruth, M., Kistner, O., Savidis-Dacho, H., Hitter, E., Crowe, B. A., Gerenčer, M., Brühl, P., Grillberger, L., Reiter, M., Tauer, C., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.08.055 · Cited by 121
A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform
Malczyk, A. H., Kupke, A., Prüfer, S., Scheuplein, V., Hutzler, S., Kreuz, D., Beißert, T., Bauer, S., Hubich-Rau, S., Tondera, C., et al. (2015) · Journal of Virology · doi:10.1128/jvi.01815-15 · Cited by 118
Neutralizing antibodies for the treatment of COVID-19
Jiang, S., Zhang, X., Yang, Y., Hotez, P. J., & Du, L. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00660-2 · Cited by 118
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study
Goepfert, P., Fu, B., Chabanon, A.-L., Bonaparte, M. I., Davis, M., Essink, B. J., Frank, I., Haney, O., Janosczyk, H., Keefer, M. C., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00147-x · Cited by 114
Pathology of Experimental SARS Coronavirus Infection in Cats and Ferrets
van den Brand, J. M. A., Haagmans, B. L., Leijten, L. M. E., van Riel, D. A. J., Martina, B. E. E., Osterhaus, A. D. M. E., & Kuiken, T. (2008) · Veterinary Pathology · doi:10.1354/vp.45-4-551 · Cited by 117
The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement
Hotez, P. J., Bottazzi, M. E., & Corry, D. B. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.04.005 · Cited by 115
Progress and Concept for COVID‐19 Vaccine Development
Wu, S. (2020) · Biotechnology Journal · doi:10.1002/biot.202000147 · Cited by 114
SARS-CoV-2 Vaccine Development: Current Status
Poland, G. A., Ovsyannikova, I. G., Crooke, S. N., & Kennedy, R. B. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.07.021 · Cited by 119
Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2
Kaur, N., Singh, R., Dar, Z., Bijarnia, R. K., Dhingra, N., & Kaur, T. (2020) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2020.104490 · Cited by 115
Medicinal Plants, Phytochemicals, and Herbs to Combat Viral Pathogens Including SARS-CoV-2
Anand, A. V., Balasubramanian, B., Kaviya, M., Kathirvel, B., Parithathvi, A., Meyyazhagan, A., Senthilkumar, N., Velayuthaprabhu, S., Muthukrishnan, S., Al-Dhabi, N. A., et al. (2021) · Molecules · doi:10.3390/molecules26061775 · Cited by 110
MVA and NYVAC as Vaccines against Emergent Infectious Diseases and Cancer
Gómez, C. E., Nájera, J. L., Krupa, M., Perdiguero, B., & Estéban, M. (2011) · Current Gene Therapy · doi:10.2174/156652311795684731 · Cited by 108
The SARS-CoV ferret model in an infection–challenge study
Chu, Y., Ali, G. D., Jia, F., Li, Q., Kelvin, D. J., Couch, R. C., Harrod, K. S., Hutt, J. A., Cameron, C., Weiss, S. R., et al. (2008) · Virology · doi:10.1016/j.virol.2007.12.032 · Cited by 107
Therapy with a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters
Roberts, A., Thomas, W. D., Guarner, J., Lamirande, E. W., Babcock, G. J., Greenough, T. C., Vogel, L., Hayes, N., Sullivan, J. L., Zaki, S. R., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/500143 · Cited by 103
Molecular Biology of the SARS-Coronavirus
Lal, S. K. (2010) · Springer eBooks · doi:10.1007/978-3-642-03683-5 · Cited by 103
Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement
Chen, W., Tao, X., Agrawal, A. S., Algaissi, A. A., Peng, B., Pollet, J. B. K., Strych, U., Bottazzi, M. E., Hotez, P. J., Lustigman, S., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.09.061 · Cited by 104
Vaccines for the prevention against the threat of MERS-CoV
Du, L., Tai, W., Zhou, Y., & Jiang, S. (2016) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1167603 · Cited by 101
The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses
Tse, L. V., Meganck, R. M., Graham, R. L., & Baric, R. S. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00658 · Cited by 101
Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines
Flanagan, K. L., Best, E., Crawford, N. W., Giles, M., Koirala, A., Macartney, K. K., Russell, F. M., Teh, B. W., & Wen, S. C.-H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.579250 · Cited by 96
SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
Chakraborty, S., Mallajosyula, V. V. A., Tato, C. M., Tan, G. S., & Wang, T. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.014 · Cited by 90
Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines
See, R. H., Petric, M., Lawrence, D. J., Mok, C. P. Y., Rowe, T., Zitzow, L. A., Karunakaran, K. P., Voss, T. G., Brunham, R. C., Gauldie, J., et al. (2008) · Journal of General Virology · doi:10.1099/vir.0.2008/001891-0 · Cited by 85
Immunoinformatics and molecular modeling approach to design universal multi-epitope vaccine for SARS-CoV-2
Khan, T., Islam, M. J., Parihar, A., Islam, R., Jerin, T. J., Dhote, R., Ali, M., Laura, F. K., & Halim, M. A. (2021) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2021.100578 · Cited by 84
Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions
Gavor, E., Choong, Y. K., Er, S. Y., Sivaraman, H., & Sivaraman, J. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.09.004 · Cited by 83
Targets and strategies for vaccine development against SARS-CoV-2
Malik, J. A., Mulla, A. H., Farooqi, T., Pottoo, F. H., Anwar, S., & Rengasamy, K. R. R. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111254 · Cited by 81
A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model
Hashem, A. M., Algaissi, A. A., Agrawal, A. S., Alamri, S. S., Alhabbab, R. Y., Sohrab, S. S., Almasoud, A. S., Alharbi, N. K., Peng, B., Russell, M. S., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz137 · Cited by 72
Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses
Gartlan, C., Tipton, T., Salguero, F. J., Sattentau, Q. J., GORRINGE, A. R., & Carroll, M. W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.882972 · Cited by 79
Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV
Lokugamage, K. G., Iwata‐Yoshikawa, N., Ito, N., Watts, D. M., Wyde, P. R., Wang, N., Newman, P. C., Tseng, C.-T. K., Peters, C. J., & Makino, S. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.11.092 · Cited by 73
Membrane Protein of Human Coronavirus NL63 Is Responsible for Interaction with the Adhesion Receptor
Naskalska, A., Dąbrowska, A., Szczepański, A., Milewska, A., Jasik, K. P., & Pyrć, K. (2019) · Journal of Virology · doi:10.1128/jvi.00355-19 · Cited by 72
Severe acute respiratory syndrome‐coronavirus‐2 spike (S) protein based vaccine candidates: State of the art and future prospects
Arashkia, A., Jalilvand, S., Mohajel, N., Afchangi, A., Azadmanesh, K., Salehi-Vaziri, ‪., Fazlalipour, M., Pouriayevali, M. H., Jalali, T., Nasab, S. D. M., et al. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2183 · Cited by 73
Immunogenicity and Protective Efficacy in Mice and Hamsters of a β-Propiolactone Inactivated Whole Virus SARS-CoV Vaccine
Roberts, A., Lamirande, E. W., Vogel, L., Baras, B., Goossens, G., Knott, I., Chen, J., Ward, J. M., Vassilev, V. B., & Subbarao, K. (2010) · Viral Immunology · doi:10.1089/vim.2010.0028 · Cited by 70
Lack of Innate Interferon Responses during SARS Coronavirus Infection in a Vaccination and Reinfection Ferret Model
Cameron, M. J., Kelvin, A. A., Leon, A. J., Cameron, C., Ran, L., Xu, L., Chu, Y.-K., Danesh, A., Yuan, F., Li, Q., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045842 · Cited by 68
A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike
Lu, M., Dravid, P., Zhang, Y., Trivedi, S., Li, A., Harder, O. E., Mahesh, K. C., Chaiwatpongsakorn, S., Zani, A., Kenney, A. D., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026153118 · Cited by 66
Vaccines against Coronaviruses: The State of the Art
Conte, C., Sogni, F., Affanni, P., Veronesi, L., Argentiero, A., & Esposito, S. (2020) · Vaccines · doi:10.3390/vaccines8020309 · Cited by 60
Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2 Vaccine Design
Wang, D., Mai, J., Zhou, W., Yu, W., Zhan, Y., Wang, N., Epstein, N. D., & Yang, Y. (2020) · Vaccines · doi:10.3390/vaccines8030355 · Cited by 60
Development and preclinical evaluation of virus‐like particle vaccine against COVID‐19 infection
Yilmaz, I. C., İpekoğlu, E. M., Bulbul, A., Turay, N., Yıldırım, M., Evcili, İ., Yilmaz, N. S., Guvencli, N., Aydin, Y., Gungor, B., et al. (2021) · Allergy · doi:10.1111/all.15091 · Cited by 63
Drug Targets in Severe Acute Respiratory Syndrome (SARS) Virus and other Coronavirus Infections
Tong, T. R. S.-W. (2009) · Infectious Disorders - Drug Targets · doi:10.2174/187152609787847659 · Cited by 56
Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
Al‐Kassmy, J., Pedersen, J., & Kobinger, G. (2020) · Viruses · doi:10.3390/v12080861 · Cited by 56
Severe Acute Respiratory Syndrome Coronavirus Infection in Vaccinated Ferrets
Darnell, M. E. R., Plant, E. P., Watanabe, H., Byrum, R., Claire, M. S., Ward, J. M., & Taylor, D. R. (2007) · The Journal of Infectious Diseases · doi:10.1086/522431 · Cited by 54
Why Have Nanotechnologies Been Underutilized in The Global Uprising Against The Coronavirus Pandemic?
Uskoković, V. (2020) · Nanomedicine · doi:10.2217/nnm-2020-0163 · Cited by 52
A 219-mer CHO-Expressing Receptor-Binding Domain of SARS-CoV S Protein Induces Potent Immune Responses and Protective Immunity
Du, L., Zhao, G., Chan, C. C. S., Li, L., He, Y., Zhou, Y., Zheng, B., & Jiang, S. (2010) · Viral Immunology · doi:10.1089/vim.2009.0090 · Cited by 47
Betacoronavirus Genomes: How Genomic Information has been Used to Deal with Past Outbreaks and the COVID-19 Pandemic
Llanes, A., Restrepo, C. M., Zuleima Caballero, E., Rajeev, S., Kennedy, M. A., & Lleonart, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124546 · Cited by 52
Ferrets are valuable models for SARS-CoV-2 research
Ciurkiewicz, M., Armando, F., Schreiner, T., de Buhr, N., Pilchová, V., Krupp-Buzimikic, V., Gabriel, G., von Köckritz‐Blickwede, M., Baumgärtner, W., Schulz, C., et al. (2022) · Veterinary Pathology · doi:10.1177/03009858211071012 · Cited by 43
Animal Models, Zoonotic Reservoirs, and Cross-Species Transmission of Emerging Human-Infecting Coronaviruses
Kane, Y., Wong, G., & Gao, G. F. (2023) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-020420-025011 · Cited by 43
State-of-the-Art of Nanodiagnostics and Nanotherapeutics against SARS-CoV-2
Derakhshan, M. A., Amani, A., & Majidi, R. F. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c22381 · Cited by 42
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
Tong, T. R. S.-W. (2006) · Perspectives in medical virology · doi:10.1016/s0168-7069(06)16004-8 · Cited by 41
Improving immunological insights into the ferret model of human viral infectious disease
Wong, J., Layton, D., Wheatley, A. K., & Kent, S. J. (2019) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12687 · Cited by 39
Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model
Kreijtz, J. H. C. M., Suezer, Y., Bodewes, R., Schwantes, A., van Amerongen, G., Verburgh, R. J., de Mutsert, G., van den Brand, J. M. A., Trierum, S. E. V.-V., Kuiken, T., et al. (2010) · Journal of General Virology · doi:10.1099/vir.0.024885-0 · Cited by 40
Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases
Perdiguero, B., Pérez, P., Marcos-Villar, L., Albericio, G., Astorgano, D., Álvarez, E., Sin, L., Gómez, C. E., García‐Arriaza, J., & Estéban, M. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168173 · Cited by 39
The impact of immuno-aging on SARS-CoV-2 vaccine development
Connors, J. R., Bell, M. R., Marcy, J., Kutzler, M. A., & Haddad, E. K. (2021) · GeroScience · doi:10.1007/s11357-021-00323-3 · Cited by 39
Immune Response to SARS-CoV-2 Vaccines
Bellamkonda, N., Lambe, U. P., Sawant, S. A., Nandi, S. S., Chakraborty, C., & Shukla, D. (2022) · Biomedicines · doi:10.3390/biomedicines10071464 · Cited by 37
Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources
Razali, R., Asis, H., & Budiman, C. (2021) · Microorganisms · doi:10.3390/microorganisms9122481 · Cited by 36
Template-based coiled-coil antigens elicit neutralizing antibodies to the SARS-coronavirus
Tripet, B., Kao, D. J., Jeffers, S. A., Holmes, K. V., & Hodges, R. S. (2006) · Journal of Structural Biology · doi:10.1016/j.jsb.2006.03.019 · Cited by 36
Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development
Khalaj‐Hedayati, A. (2020) · Journal of Immunology Research · doi:10.1155/2020/7201752 · Cited by 35

Authors: CZUB, M., WEINGARTL, H., CZUB, S., HE, R., & CAO, J.
Affiliations: Canadian Science Centre for Human and Animal Health (CA)
University of Manitoba (CA)
Corresponding author: CAO, J
ORCID: CZUB, S
CAO, J
Venue: Vaccine
Publisher: Elsevier BV
Published: 2005-03-18
Volume: 23
Issue: 17-18
Pages: 2273-2279
ISSN: 0264-410X (ISSN-L)
DOI: 10.1016/j.vaccine.2005.01.033
PMC: PMC7115540
OpenAlex: W2169462787
Cited by: 180
References: 17
Citations by year: 2026: 1 · 2024: 4 · 2023: 9 · 2022: 14 · 2021: 36 · 2020: 55 · 2019: 5 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 4 · 2013: 1 · 2012: 4
FWCI: 5.56
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Vaccine (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Canadian Food Inspection Agency
Health Canada
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Life Sciences › Immunology and Microbiology › Virology › Poxvirus research and outbreaks
Keywords: SARS-CoV, modified vaccinia Ankara, recombinant vaccine, spike protein, nucleocapsid protein, ferrets, vaccine efficacy, vaccine safety, liver necrosis, inflammation
MeSH terms: Coronavirus Nucleocapsid Proteins, Animals, Antigens, Viral, Base Sequence, DNA, Viral, Ferrets, Hepatitis, Viral, Animal, Male, Membrane Glycoproteins, RNA, Viral, Vaccines, Synthetic, Viral Envelope Proteins, Viral Vaccines, Nucleocapsid Proteins, Severe Acute Respiratory Syndrome, Severe acute respiratory syndrome-related coronavirus, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks